Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection.

Nichols MJ, Gates TM, Soares JR, Moffat KJ, Rae CD, Brew BJ, Cysique LA.

AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002042. [Epub ahead of print]

PMID:
30325766
2.

Chronic Human Immunodeficiency Virus Infection With and Without Comorbidities Appears to Converge Toward Early Pathological Brain Aging.

Cysique LA.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Oct;3(10):820-821. doi: 10.1016/j.bpsc.2018.08.005. No abstract available.

PMID:
30297029
3.

Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia.

Mukherjee T, Sakthivel R, Fong HY, McStea M, Chong ML, Omar SF, Chin AV, Kamaruzzaman S, Kamarulzaman A, Rajasuriar R, Cysique LA.

AIDS Behav. 2018 Oct;22(10):3226-3233. doi: 10.1007/s10461-018-2073-x.

4.

The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy.

Bundell C, Brunt SJ, Cysique LA, Brusch A, Brew BJ, Price P.

Pathology. 2018 Apr;50(3):313-316. doi: 10.1016/j.pathol.2017.10.017. Epub 2018 Feb 17.

PMID:
29463387
5.

Covertly active and progressing neurochemical abnormalities in suppressed HIV infection.

Cysique LA, Jugé L, Gates T, Tobia M, Moffat K, Brew BJ, Rae C.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 3;5(1):e430. doi: 10.1212/NXI.0000000000000430. eCollection 2018 Jan.

6.

HIV-Associated Neurocognitive Disorders: A Global Perspective.

Saloner R, Cysique LA.

J Int Neuropsychol Soc. 2017 Oct;23(9-10):860-869. doi: 10.1017/S1355617717001102. Review.

7.

Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.

Siefried KJ, Mao L, Cysique LA, Rule J, Giles ML, Smith DE, McMahon J, Read TR, Ooi C, Tee BK, Bloch M, de Wit J, Carr A; PAART study investigators.

AIDS. 2018 Jan 2;32(1):35-48. doi: 10.1097/QAD.0000000000001685.

8.

HIV-related cognitive decline despite viral suppression and complex confounds in American women.

Cysique LA, Becker JT.

Neurology. 2017 Oct 10;89(15):1540-1541. doi: 10.1212/WNL.0000000000004503. Epub 2017 Sep 13. No abstract available.

PMID:
28904090
9.

Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.

Cysique LA, Soares JR, Geng G, Scarpetta M, Moffat K, Green M, Brew BJ, Henry RG, Rae C.

J Neurovirol. 2017 Aug;23(4):548-549. doi: 10.1007/s13365-017-0542-z. No abstract available.

PMID:
28755142
10.

Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.

Siefried KJ, Mao L, Kerr S, Cysique LA, Gates TM, McAllister J, Maynard A, de Wit J, Carr A; PAART study investigators.

PLoS One. 2017 Apr 3;12(4):e0174613. doi: 10.1371/journal.pone.0174613. eCollection 2017.

11.

White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.

Cysique LA, Soares JR, Geng G, Scarpetta M, Moffat K, Green M, Brew BJ, Henry RG, Rae C.

J Neurovirol. 2017 Aug;23(4):539-547. doi: 10.1007/s13365-017-0524-1. Epub 2017 Mar 21. Erratum in: J Neurovirol. 2017 Jul 28;:.

PMID:
28324319
12.

Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.

Kamminga J, Lal L, Wright EJ, Bloch M, Brew BJ, Cysique LA.

Curr HIV/AIDS Rep. 2017 Jun;14(3):83-92. doi: 10.1007/s11904-017-0349-9. Review.

PMID:
28284004
13.

Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity.

Gott C, Gates T, Dermody N, Brew BJ, Cysique LA.

PLoS One. 2017 Mar 6;12(3):e0171887. doi: 10.1371/journal.pone.0171887. eCollection 2017.

14.

Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.

Kamminga J, Bloch M, Vincent T, Carberry A, Brew BJ, Cysique LA.

J Clin Exp Neuropsychol. 2017 Oct;39(8):753-767. doi: 10.1080/13803395.2016.1263282. Epub 2017 Jan 4.

PMID:
28052738
15.

A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.

Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA.

Clin Infect Dis. 2016 Sep 1;63(5):687-693. doi: 10.1093/cid/ciw399. Epub 2016 Jun 19.

16.

Identifying Neurocognitive Decline at 36 Months among HIV-Positive Participants in the CHARTER Cohort Using Group-Based Trajectory Analysis.

Brouillette MJ, Yuen T, Fellows LK, Cysique LA, Heaton RK, Mayo NE.

PLoS One. 2016 May 18;11(5):e0155766. doi: 10.1371/journal.pone.0155766. eCollection 2016.

17.

Short Communication: Do Cytomegalovirus Antibody Levels Associate with Age-Related Syndromes in HIV Patients Stable on Antiretroviral Therapy?

Brunt SJ, Cysique LA, Lee S, Burrows S, Brew BJ, Price P.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):567-72. doi: 10.1089/AID.2015.0328. Epub 2016 Mar 16.

PMID:
26876416
18.

Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ.

AIDS. 2016 Feb 20;30(4):591-600. doi: 10.1097/QAD.0000000000000951.

PMID:
26825032
19.

The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.

Gates TM, Cysique LA.

CNS Drugs. 2016 Jan;30(1):53-69. doi: 10.1007/s40263-015-0302-7. Review.

20.

Advancing research in NeuroAIDS using collaboration and public data sharing.

Cysique LA.

BMC Med Genomics. 2015 Nov 11;8:76. doi: 10.1186/s12920-015-0150-9.

21.

The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults.

Cysique LA, Dermody N, Carr A, Brew BJ, Teesson M.

J Neurovirol. 2016 Feb;22(1):56-65. doi: 10.1007/s13365-015-0368-5. Epub 2015 Aug 25.

PMID:
26304840
22.

APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.

Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.

BMC Neurol. 2015 Apr 1;15:51. doi: 10.1186/s12883-015-0298-0.

23.

Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition.

Cysique LA, Hey-Cunningham WJ, Dermody N, Chan P, Brew BJ, Koelsch KK.

PLoS One. 2015 Apr 8;10(4):e0120488. doi: 10.1371/journal.pone.0120488. eCollection 2015.

24.

HIV eradication symposium: will the brain be left behind?

Brew BJ, Robertson K, Wright EJ, Churchill M, Crowe SM, Cysique LA, Deeks S, Garcia JV, Gelman B, Gray LR, Johnson T, Joseph J, Margolis DM, Mankowski JL, Spencer B.

J Neurovirol. 2015 Jun;21(3):322-34. doi: 10.1007/s13365-015-0322-6. Epub 2015 Mar 7.

25.

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TR, Price RW; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238.

26.

Commentaries on Viewpoint: The ongoing need for good physiological investigation: Obstructive sleep apnea in HIV patients as a paradigm.

Zuo L, Hemmelgarn BT, Jouett NP, Smith ML, Eugenín J, Beltrán-Castillo S, von Bernhardi R, de Figueiredo Müller-Ribeiro FC, Ribeiro-Marins F, Fontes MA, Cysique LA, Gandevia SC, Tellez HF, Mekjavic IB, Perlitz V, Kerkhof PL, de Munck J, Moret-Bonillo V, Nieman G, Gatto LA.

J Appl Physiol (1985). 2015 Jan 15;118(2):247-50. doi: 10.1152/japplphysiol.00989.2014. No abstract available.

27.

Lessons to be learned from the largest study of cognition in American women with HIV disease.

Cysique LA, Becker JT.

Neurology. 2015 Jan 20;84(3):220-1. doi: 10.1212/WNL.0000000000001166. Epub 2014 Dec 24. No abstract available.

PMID:
25540319
28.

Should longitudinal multisite studies become the new standard for investigating neurocognitive functions in HIV infection?

Cysique LA.

Clin Infect Dis. 2015 Feb 1;60(3):481-2. doi: 10.1093/cid/ciu863. Epub 2014 Oct 31. No abstract available.

PMID:
25362203
29.

Primary HIV infection alters brain neurochemistry, but does antiretroviral treatment help?

Cysique LA, Koelsch KK.

Neurology. 2014 Oct 28;83(18):1588-9. doi: 10.1212/WNL.0000000000000947. Epub 2014 Sep 26. No abstract available.

PMID:
25261499
30.

The effects of HIV and aging on brain functions: proposing a research framework and update on last 3 years' findings.

Cysique LA, Brew BJ.

Curr Opin HIV AIDS. 2014 Jul;9(4):355-64. doi: 10.1097/COH.0000000000000078. Review.

PMID:
24871088
31.

HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research.

Cysique LA, Heaton RK, Kamminga J, Lane T, Gates TM, Moore DM, Hubner E, Carr A, Brew BJ.

J Neurovirol. 2014 Jun;20(3):258-68. doi: 10.1007/s13365-014-0242-x. Epub 2014 Apr 3.

32.

Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide.

Kamminga J, Cysique LA, Lu G, Batchelor J, Brew BJ.

Curr HIV/AIDS Rep. 2013 Dec;10(4):342-55. doi: 10.1007/s11904-013-0176-6. Review.

33.

HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study.

Cysique LA, Moffat K, Moore DM, Lane TA, Davies NW, Carr A, Brew BJ, Rae C.

PLoS One. 2013 Apr 19;8(4):e61738. doi: 10.1371/journal.pone.0061738. Print 2013.

34.

The cost of silencing HIV in the brain.

Wiley CA, Cysique LA.

Neurology. 2013 Apr 9;80(15):1363-4. doi: 10.1212/WNL.0b013e31828c3077. Epub 2013 Mar 13. No abstract available.

PMID:
23486870
35.

Facial emotional processing in HIV infection: relation to neurocognitive and neuropsychiatric status.

Lane TA, Moore DM, Batchelor J, Brew BJ, Cysique LA.

Neuropsychology. 2012 Nov;26(6):713-22. doi: 10.1037/a0029964. Epub 2012 Sep 17.

PMID:
22984798
36.

The influence of HLA on HIV-associated neurocognitive impairment in Anhui, China.

Schrier RD, Gupta S, Riggs P, Cysique LA, Letendre S, Jin H, Spector SA, Singh KK, Wolfson T, Wu Z, Hong KX, Yu X, Shi C, Heaton RK; HNRC Group.

PLoS One. 2012;7(5):e32303. doi: 10.1371/journal.pone.0032303. Epub 2012 May 31.

37.

Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Cruse B, Cysique LA, Markus R, Brew BJ.

J Neurovirol. 2012 Aug;18(4):264-76. doi: 10.1007/s13365-012-0092-3. Epub 2012 Apr 14. Review.

PMID:
22528476
38.

The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future.

Cysique LA, Bain MP, Brew BJ, Murray JM.

Sex Health. 2011 Dec;8(4):541-50. doi: 10.1071/SH11003.

PMID:
22127041
39.

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.

Cysique LA, Waters EK, Brew BJ.

BMC Neurol. 2011 Nov 22;11:148. doi: 10.1186/1471-2377-11-148. Review.

40.

Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

Cysique LA, Brew BJ.

J Neurovirol. 2011 Apr;17(2):176-83. doi: 10.1007/s13365-011-0021-x. Epub 2011 Mar 17.

PMID:
21416169
41.

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change.

Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK; CHARTER Group; HNRC Group.

J Clin Exp Neuropsychol. 2011 Jun;33(5):505-22. doi: 10.1080/13803395.2010.535504. Epub 2011 Mar 7.

42.

HIV and age do not substantially interact in HIV-associated neurocognitive impairment.

Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ.

J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):83-9. doi: 10.1176/appi.neuropsych.23.1.83.

PMID:
21304143
43.

Statistical integration of 1H NMR and MRS data from different biofluids and tissues enhances recovery of biological information from individuals with HIV-1 infection.

Maher AD, Cysique LA, Brew BJ, Rae CD.

J Proteome Res. 2011 Apr 1;10(4):1737-45. doi: 10.1021/pr1010263. Epub 2011 Feb 23.

PMID:
21244037
44.

Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China.

Heaton RK, Cysique LA, Jin H, Shi C, Yu X, Letendre S, Franklin DR Jr, Ake C, Vigil O, Atkinson JH, Marcotte TD, Grant I, Wu Z; HNRC group.

J Neurovirol. 2010 Mar;16(2):185-8. doi: 10.3109/13550284.2010.481820. No abstract available.

45.

HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon.

Kanmogne GD, Kuate CT, Cysique LA, Fonsah JY, Eta S, Doh R, Njamnshi DM, Nchindap E, Franklin DR Jr, Ellis RJ, McCutchan JA, Binam F, Mbanya D, Heaton RK, Njamnshi AK.

BMC Neurol. 2010 Jul 13;10:60. doi: 10.1186/1471-2377-10-60.

46.

Alzheimer disease and HIV: a tangled story.

Brew BJ, Cysique LA.

Neurology. 2010 Jul 13;75(2):105-6. doi: 10.1212/WNL.0b013e3181e7b6a4. Epub 2010 Jun 9. No abstract available.

PMID:
20534886
47.

A screening algorithm for HIV-associated neurocognitive disorders.

Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ.

HIV Med. 2010 Nov;11(10):642-9. doi: 10.1111/j.1468-1293.2010.00834.x.

48.

Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China.

Cysique LA, Letendre SL, Ake C, Jin H, Franklin DR, Gupta S, Shi C, Yu X, Wu Z, Abramson IS, Grant I, Heaton RK; HIV Neurobehavioral Research Center group.

AIDS. 2010 Apr 24;24(7):983-90. doi: 10.1097/QAD.0b013e32833336c8.

49.

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.

Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ.

Neurology. 2009 Aug 4;73(5):342-8. doi: 10.1212/WNL.0b013e3181ab2b3b. Epub 2009 May 27.

50.

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Cysique LA, Brew BJ.

Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9. Review.

PMID:
19424802

Supplemental Content

Loading ...
Support Center